A distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease

NeuroImage

Volumn 40, Issue 3, 2008, Pages 1251-1256

  Truchot, L ^a,b,c,d   Costes, N ^b,c   Zimmer, L ^a,b,c   Laurent, B ^e,f   Le Bars, D ^a,b   Thomas Anterion C ^e,f   Mercier, B ^a,d   Hermier, M ^a   Vighetto, A ^a,c,d   Krolak Salmon, P ^a,c,d  

^a HÔPITAL NEUROLOGIQUE   (France)

^b CERMEP IMAGERIE DU VIVANT   (France)

^c Inst Federatif Neurosci Lyon   (France)

^d Memory Research Resource Centre for Alzheimer's Disease of Lyon   (France)

^e SERVICE DE NEUROLOGIE   (France)

^f Memory Research Resource Centre for Alzheimer's Disease of Saint Etienne   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 METHYLPHENYL) 1 [2 (N 2'' PYRIDINYL) 4 FLUOROBENZAMIDO]ETHYLPIPERAZINE F 18; FLUORINE 18; PIPERAZINE DERIVATIVE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; 4 (2' METHOXYPHENYL) 1 (2' (N 2' PYRIDINYL) P (18F)FLUOROBENZAMIDO )ETHYLPIPERAZINE; 4-(2'-METHOXYPHENYL)-1-(2'-(N-2'-PYRIDINYL)-P-(18F)FLUOROBENZAMIDO )ETHYLPIPERAZINE; DIAGNOSTIC AGENT; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; FEMALE; HIPPOCAMPUS; HUMAN; IMAGE PROCESSING; LIMBIC CORTEX; LIMBIC SYSTEM; MALE; MEASUREMENT; NEUROIMAGING; OCCIPITAL CORTEX; OCCIPITAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR DENSITY; SEROTONIN METABOLISM; SEROTONINERGIC NERVE; SEROTONINERGIC SYSTEM; SUBICULUM; UPREGULATION; BRAIN; COMPARATIVE STUDY; HEMISPHERIC DOMINANCE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; SCINTISCANNING;

AGED; ALZHEIMER DISEASE; AMNESIA; BRAIN; COGNITION DISORDERS; FEMALE; FUNCTIONAL LATERALITY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIMBIC SYSTEM; MALE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTOR, SEROTONIN, 5-HT1A;

EID: 40849097282     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2008.01.030     Document Type: Article

References (36)

1. 18F-MPPF as a tool for the in vivo imaging of 5-HT1A receptor in animal and human brain. Neuropharmacology 52 (2007) 695-707
2. Bachy-Langedock N. Batterie d'examen des troubles en denomination (1989), Editest, Bruxelles
3. Bantick R.A., Rabiner E.A., Hirani E., de Vries M.H., Hume S.P., and Grasby P.M. Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacology 29 (2004) 847-859
4. Braak H., and Braak E. Morphological changes in the human cerebral cortex in dementia. J. Hirnforsch. 32 (1991) 277-282
5. Beck A.T., Weissman A., Lester D., and Trexler L. The measurement of pessimism: the hopelessness scale. J. Consult. Clin. Psychol. 42 (1974) 861-865
6. Bookheimer S.Y., Strojwas M.H., Cohen M.S., Saunders A.M., Pericak-Vance M.A., Mazziotta J.C., and Small G.W. Patterns of brain activation in people at risk for Alzheimer's disease. N. Engl. J. Med. 343 (2000) 450-456
7. Boussion N., Hatt M., Lamare F., Bizais Y., Turzo A., Cheze-Le Rest C., and Visvikis D. A multiresolution image based approach for correction of partial volume effects in emission tomography. Phys. Med. Biol. 51 7 (2006) 1857-1876
8. Cardebat D., Doyon B., Puel M., Goulet P., and Joanette Y. Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol. Belg. 90 (1990) 207-217
9. Chen Y., and Penington N.J. Differential effects of protein kinase C activation on 5-HT1A receptor coupling to Ca2+ and K+ currents in rat serotonergic neurones. J. Physiol. 496 Pt 1 (1996) 129-137
10. Chen C.P., Alder J.T., Bowen D.M., Esiri M.M., McDonald B., Hope T., Jobst K.A., and Francis P.T. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J. Neurochem. 66 (1996) 1592-1598
11. Collins D., Zijdenbos A., Baar W., and Evans A. ANIMAL+INSECT: improved cortical structure segmentation. In: Kuba A.S.M., and Todd-Pokropek A. (Eds). Proceedings of the Annual Symposium on Information Processing in Medical Imaging (1999) 210-223
12. Costes N., Merlet I., Zimmer L., Lavenne F., Cinotti L., Delforge J., Luxen A., Pujol J.-F., and Le Bars D. Modeling [18F]MPPF PET kinetics for the determination of 5-HT1A concentration with multi-injection. J. Cereb. Blood Flow Metab. 22 6 (2002) 753-763
13. Costes N., Merlet I., Ostrowsky K., Faillenot I., Lavenne F., Zimmer L., Ryvlin P., and Le Bars D. A 18F-MPPF PET normative database of 5-HT1A receptor binding in men and women over aging. J. Nucl. Med. 46 (2005) 1980-1989
14. Costes N., and Reilhac A. Evaluation of PET tracer binding recovered by partial volume correction technique in case of hippocampic atrophy. IEEE Nuclear Science Symposium & Medical Imaging Conference (2006)
15. Delacourte A., David J.P., Sergeant N., Buée L., Waltez A., and Vermersch P. The biochemical pathways of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 52 (1999) 1158-1165
16. Dickerson B.C., Salat D.H., Bates J.F., Atiya M., Killiany R.J., Greve D.N., Dale A.M., Stern C.E., Blacker D., Albert M.S., and Sperling R.A. Medial temporal lobe function and structure in mild cognitive impairment. Ann. Neurol. 56 (2004) 27-35
17. Dickerson B.C., Salat D.H., Greve D.N., Chua E.F., Rand-Giovannetti E., Rentz D.M., Bertram L., Mullin K., Tanzi R.E., Blacker D., Albert M.S., and Sperling M.D. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 65 (2005) 404-411
18. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., and Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 8 (2007) 667-669
19. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-198
20. Gunn R.N., Lammertsma A.A., Hume S.P., and Cunningham V.J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage 6 (1997) 279-287
21. Jin K., Peel A.L., Mao X.O., Xie L., Cottrell B.A., Henshall D.C., and Greenberg D.A. Increased hippocampal neurogenesis in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 343-347
22. Kepe V., Barrio J.R., Huang S.C., Ercoli L., Siddarth P., Shoghi-Jadid K., Cole G.M., Satyamurthy N., Cummings J.L., Small G.W., and Phelps M.E. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 702-707
23. Lanctôt K.L., Hussey D.F., Herrmann N., Black S.E., Rusjan P.M., Wilson A.A., Houle S., Kozloff N., Verhoeff N.P., and Kapur S. A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease. Am. J. Geriatr. Psychiatry 15 (2007) 888-898
24. Le Bars D., Lemaire C., Ginovart N., Plenevaux A., Aerts J., Brihaye C., Hassoun W., Leviel V., Mekhsian P., Weissmann D., Pujol J.F., Luxen A., and Comar D. High-yield radiosynthesis and preliminary in vivo evaluation of p-[18F]MPPF, a fluoro analog of WAY-100635. Nucl. Med. Biol. 25 (1998) 343-350
25. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
26. Mevel K., Desgranges B., Baron J.C., Landeau B., De la Sayette V., Viader F., Eustache F., and Chételat G. Detecting hippocampal hypometabolism in mild cognitive impairment using automatic voxel-based approaches. NeuroImage 37 1 (2007) 18-25
27. Merlet I., Ryvlin P., Costes N., Dufournel D., Isnard J., Faillenot I., Ostrowsky K., Lavenne F., Le Bars D., and Mauguiere F. Statistical parametric mapping of 5-HT1A receptor binding in temporal lobe epilepsy with hippocampal ictal onset on intracranial EEG. NeuroImage 22 2 (2004) 886-896
28. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43 (1993) 2412-2414
29. 18F]p-MPPF. Nucl. Med. Biol. 27 (2000) 473-476
30. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., Ritchie K., Rossor M., Thal L., and Winblad B. Current concepts in mild cognitive impairment. Arch. Neurol. 58 (2001) 1985-1992
31. Reitan R.M., and Wolfson D. The Halstead-Reitan Neuropsychological tests Battery (1985), Tucson, Neuropsychology Press
32. Samuraki M., Ichiro M., Wei-Ping C., et al. FDG PET in patients with mild Alzheimer's disease before and after correction for cortical atrophy. J. Nucl. Med. 47 (2006) 118P
33. Teo B.K., Seo Y., Bacharach S.L., Carrasquillo J.A., Libutti S.K., Shukla H., Hasegawa B.H., Hawkins R.A., and Franc B.L. Partial-volume correction in PET: validation of an iterative postconstruction method with phantom and patient data. J. Nucl. Med. 48 5 (2007) 802-810
34. Truchot L., Costes N., Zimmer L., Laurent B., Le Bars D., Thomas-Antérion C., Croisile B., Mercier B., Hermier M., Vighetto A., and Krolak-Salmon P. Up regulation of hippocampal serotonin metabolism in Mild Cognitive Impairment. Neurology 69 (2007) 1012-1017
35. Van Der Linden M. Evaluation des troubles de la mémoire (2004), Solal
36. Wechsler D. Wechsler Memory Scale-revised (1987), the Psychological Corporation, San Antonio, Tx